Viz.ai said the Viz Subdural Hematoma (SDH) artificial intelligence (AI) algorithm provides automatic detection of acute and chronic subdural hemorrhages, facilitating timely triage and treatment of patients.
Viz Subdural Hematoma (SDH), a new artificial intelligence (AI)-powered algorithm for diagnosing subdural hemorrhages, has garnered 510(k) clearance from the Food and Drug Administration (FDA), according to Viz.ai, the manufacturer of the module.
Noting a rising incidence of subdural hematomas, Viz.ai said the SDH algorithm demonstrated sensitivity and specificity rates of 94 and 92 percent respectively in a multicenter trial of over 500 patients.1,2
“The algorithm is very sensitive and specific, significantly increasing the number of subdural hemorrhages detected and ensuring patients receive the necessary follow-up from this potentially life-threatening disease,” maintained Jayme Strauss, the chief clinical officer at Viz.ai.
The company emphasizes that Viz SDH is currently the only AI-powered platform specifically geared to identifying and differentiating between acute and chronic subdural hemorrhages. Jason Davies, M.D., Ph.D., said this is a key benefit given the different treatment pathways for these conditions.
“Acute (subdural hemorrhages) require urgent intervention. Therefore, prompt notification will allow us to improve outcomes in emergent cases. Chronic (subdural hemorrhages) have a very different pathway and having an algorithm that identifies both can allow us to take better care of our patients,” noted Dr. Davies, an associate professor of neurosurgery and biomedical informatics at the State University of New York (SUNY) at Buffalo. “The Viz.ai algorithm ensures that patients are quickly identified and routed to the appropriate therapy.”
References
1. Neifert SN, Chaman EK, Hardigan T, et al. Increases in subdural hematoma with an aging population – the future of Amerivcan cerebrovascular disease. World Neurosurg. 2020;141;e166-e174.
2. Viz.ai. Viz.ai receives FDA 510(k) clearance for Viz SDH. Available at: https://www.viz.ai/press-release/viz-ai-receives-fda-510-k-clearance-for-viz-sdh . Published July 27, 2022. Accessed August 1, 2022.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.